1. Empagliflozin in heart failure with a preserved ejection fraction
- Author
-
Bela Merkely, Nikolaus Marx, Subodh Verma, Michele Senni, Eduardo Chuquiure-Valenzuela, James L. Januzzi, Vijay K. Chopra, Dong-Ju Choi, Stefan D. Anker, Stefano Taddei, Ileana L. Piña, Juan Esteban Gomez-Mesa, Jose R Gonzalez-Juanatey, Dragos Vinereanu, Sergio V. Perrone, Faiez Zannad, Jian Zhang, Carolyn Su Ping Lam, Stuart J. Pocock, Stefan Janssens, Iain Squire, Waheed Jamal, Hans-Peter Brunner-La Rocca, Peter E. Carson, Javed Butler, David K.L. Sim, EMPEROR-Preserved Trial Investigators, Stephen J. Nicholls, Hiroyuki Tsutsui, Janet Schnee, Martina Brueckmann, João Pedro Ferreira, Piotr Ponikowski, Naveed Sattar, Gerasimos Filippatos, Sven Schnaidt, Edimar Bocchi, Michael Böhm, Jindrich Spinar, Cordula Zeller, Nadia Giannetti, Milton Packer, Anker, S, Butler, J, Filippatos, G, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure-Valenzuela, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Carson, P, Lam, C, Marx, N, Zeller, C, Sattar, N, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial, I, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H02 Cardiomyopathy
- Subjects
Adult ,Male ,medicine.medical_specialty ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Empagliflozin ,Preserved Ejection Fraction ,Placebo ,chemistry.chemical_compound ,All institutes and research themes of the Radboud University Medical Center ,Double-Blind Method ,Glucosides ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Benzhydryl Compounds ,Sodium-Glucose Transporter 2 Inhibitors ,Heart Failure ,Ejection fraction ,business.industry ,Hazard ratio ,Stroke Volume ,General Medicine ,Stroke volume ,medicine.disease ,SPIRONOLACTONE ,Hospitalization ,chemistry ,Cardiovascular Diseases ,Heart failure ,Chronic Disease ,Cardiology ,Spironolactone ,Female ,business - Abstract
Item does not contain fulltext BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P
- Published
- 2021